Adding Regorafenib in First-Line 'Promising' in Gastric Cancer

(MedPage Today) -- Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy regimen for HER2-negative metastatic esophagogastric cancer demonstrated "promising" activity in a single-arm phase II study, according to researchers...

https://www.medpagetoday.com/hematologyoncology/othercancers/106192

Source: MedPage Today Gastroenterology - September 6, 2023 Category: Gastroenterology Source Type: news